Processing Magazine

Bristol-Myers, Lilly receive FDA approval to market cancer drug for wider use

November 8, 2011

WASHINGTON — Bristol-Myers Squibb Co. and Eli Lilly & Co. received FDA approval on Monday to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors, Bloomberg reported.

The medicine was cleared for use with chemotherapy to treat patients with head and neck cancer that has spread.

Erbitux already is approved in the U.S. to treat colon cancer and head and neck tumors that haven’t spread.